Nurix Therapeutics Inc
NRIX11.270USD
+0.230+2.08%
交易中 （美东）报价延迟15分钟
861.41M总市值
亏损市盈率 TTM
关于 Nurix Therapeutics Inc 公司
Nurix Therapeutics, Inc. 是一家临床阶段生物制药公司。该公司专注于发现、开发和商业化靶向蛋白质降解药物，旨在改善癌症和炎症疾病患者的治疗选择。其全资拥有的临床阶段产品线包括三种在研候选药物：NX-5948，一种高选择性布鲁顿酪氨酸激酶 (BTK) 降解剂；NX-2127，一种 BTK 和转录因子 IKZF1 (Ikaros) 和 IKZF3 (Aiolos) 的双重降解剂；NX-1607，一种 Casitas B 系淋巴瘤原癌基因 B (CBL-B) 抑制剂，CBL-B 是一种 E3 连接酶，可调节多种免疫细胞类型（包括 T 细胞和 NK 细胞）的激活。该公司还在其临床前产品线中推进多种降解剂和降解抗体偶联物 (DAC)。其合作药物研发管线包括 IRAK4 和 STAT6 的临床前阶段降解剂以及多个附加项目。
公司简介
公司代码NRIX
公司名称Nurix Therapeutics Inc
上市日期Jul 24, 2020
CEODr. Arthur T. Sands, M.D., Ph.D.
员工数量286
证券类型Ordinary Share
年结日Jul 24
公司地址1700 Owens St Ste 205
城市SAN FRANCISCO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94158
电话14156605320
网址https://www.nurixtx.com/
公司代码NRIX
上市日期Jul 24, 2020
CEODr. Arthur T. Sands, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Arthur T. Sands, M.D., Ph.D.
Dr. Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
908.33K
--
Dr. Christine Ring, J.D., Ph.D.
Dr. Christine Ring, J.D., Ph.D.
Chief Legal Officer, Chief Compliance Officer, Secretary
Chief Legal Officer, Chief Compliance Officer, Secretary
44.01K
+17.93%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
33.33K
--
Mr. Hans van Houte
Mr. Hans van Houte
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Wolffe, Ph.D.
Ms. Elizabeth Wolffe, Ph.D.
Investor Relations
Investor Relations
--
--
Mr. Paul M. Silva
Mr. Paul M. Silva
Independent Director
Independent Director
--
--
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Edward C. (Ed) Saltzman
Mr. Edward C. (Ed) Saltzman
Independent Director
Independent Director
--
--
Dr. Roy D. Baynes, M.D., Ph.D.
Dr. Roy D. Baynes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Lori A. Kunkel, M.D.
Dr. Lori A. Kunkel, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Arthur T. Sands, M.D., Ph.D.
Dr. Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
908.33K
--
Dr. Christine Ring, J.D., Ph.D.
Dr. Christine Ring, J.D., Ph.D.
Chief Legal Officer, Chief Compliance Officer, Secretary
Chief Legal Officer, Chief Compliance Officer, Secretary
44.01K
+17.93%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
33.33K
--
Mr. Hans van Houte
Mr. Hans van Houte
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Wolffe, Ph.D.
Ms. Elizabeth Wolffe, Ph.D.
Investor Relations
Investor Relations
--
--
Mr. Paul M. Silva
Mr. Paul M. Silva
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月1日 周五
更新时间: 8月1日 周五
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
12.02%
BlackRock Institutional Trust Company, N.A.
7.81%
Deep Track Capital LP
7.19%
The Vanguard Group, Inc.
5.76%
Redmile Group, LLC
5.30%
Other
61.91%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
12.02%
BlackRock Institutional Trust Company, N.A.
7.81%
Deep Track Capital LP
7.19%
The Vanguard Group, Inc.
5.76%
Redmile Group, LLC
5.30%
Other
61.91%
股东类型
持股股东
占比
Investment Advisor
44.05%
Hedge Fund
30.81%
Investment Advisor/Hedge Fund
29.53%
Research Firm
3.16%
Venture Capital
1.77%
Individual Investor
1.41%
Private Equity
0.97%
Pension Fund
0.47%
Sovereign Wealth Fund
0.42%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
377
87.00M
113.82%
-2.77M
2025Q1
389
86.54M
113.52%
-3.63M
2024Q4
375
82.62M
109.55%
+7.81M
2024Q3
364
70.42M
104.89%
-2.21M
2024Q2
348
68.70M
107.62%
+7.14M
2024Q1
317
52.13M
105.94%
-5.88M
2023Q4
312
49.16M
101.34%
-6.38M
2023Q3
304
48.27M
100.23%
-5.64M
2023Q2
307
47.72M
99.11%
-5.99M
2023Q1
304
45.84M
96.69%
-8.16M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
9.19M
12.06%
-370.83K
-3.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.97M
7.83%
+323.12K
+5.72%
Mar 31, 2025
Deep Track Capital LP
5.50M
7.21%
+1.38M
+33.33%
Mar 31, 2025
The Vanguard Group, Inc.
4.40M
5.77%
+69.86K
+1.61%
Mar 31, 2025
Redmile Group, LLC
4.05M
5.32%
-140.70K
-3.36%
Mar 31, 2025
Commodore Capital LP
3.98M
5.22%
+128.91K
+3.35%
Mar 31, 2025
Baker Bros. Advisors LP
3.88M
5.09%
--
--
Mar 31, 2025
Wellington Management Company, LLP
3.19M
4.18%
-397.86K
-11.09%
Mar 31, 2025
State Street Global Advisors (US)
2.86M
3.75%
+57.96K
+2.07%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.82M
3.7%
-99.19K
-3.40%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ARK Genomic Revolution ETF
1.72%
Tema Oncology ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
SPDR S&P Biotech ETF
0.22%
iShares Micro-Cap ETF
0.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.12%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
iShares Biotechnology ETF
0.09%
Fidelity Fundamental Small-Mid Cap ETF
0.08%
查看更多
ARK Genomic Revolution ETF
占比1.72%
Tema Oncology ETF
占比1.25%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.86%
SPDR S&P Biotech ETF
占比0.22%
iShares Micro-Cap ETF
占比0.19%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.12%
Invesco Nasdaq Biotechnology ETF
占比0.1%
ProShares Ultra Nasdaq Biotechnology
占比0.1%
iShares Biotechnology ETF
占比0.09%
Fidelity Fundamental Small-Mid Cap ETF
占比0.08%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
